What is the response rate for talquetamab and teclistamab combination in relapsed/refractory multiple myeloma?
The combination of two bispecific antibodies, talquetamab (targeting GPRC5D) and teclistamab (targeting BCMA), has been studied in patients with relapsed/refractory multiple myeloma, particularly those with extramedullary disease (plasmacytomas outside the bone marrow). The phase 2 RedirecTT-1 trial reported an overall response rate of 79%, meaning nearly 8 out of 10 patients had a significant reduction in their cancer. However, this result comes from a single study with a short follow-up, and the treatment carries notable risks, including infections.
What the research says
The RedirecTT-1 trial, a phase 2 study, evaluated the dual bispecific antibody combination in patients with relapsed/refractory multiple myeloma and extramedullary disease. The overall response rate was 79%, and the 12-month progression-free survival (time without cancer worsening) was 61% 9. These results are promising, especially since many patients had already received multiple prior therapies, including BCMA-directed CAR-T therapy 9. However, the study had a single-arm design (no comparison group) and a median follow-up of only 12.6 months, so longer-term data are needed 9.
In terms of safety, grade 3-4 infections occurred in 31% of patients, and there were five treatment-related deaths 9. This toxicity burden is significant and may limit use outside specialized centers. For context, a meta-analysis of teclistamab alone found any-grade infections in 56.5% of patients and grade ≥3 infections in 27.6% 5. The combination may carry a higher infection risk, though direct comparisons are lacking.
Bispecific antibodies like teclistamab and talquetamab are generally considered highly effective in relapsed/refractory multiple myeloma, but they require careful management of side effects such as cytokine release syndrome and infections 8. The dual targeting approach aims to overcome resistance, but the evidence is still evolving, and randomized trials are needed to confirm its benefits over other strategies 9.
What to ask your doctor
- What is the overall response rate for the talquetamab and teclistamab combination in my specific situation?
- How does the infection risk with this combination compare to other treatments I might consider?
- Are there any ongoing clinical trials or newer data on this combination since the RedirecTT-1 study?
- What is the expected duration of response, and how often would I need monitoring?
- Given my prior treatments and overall health, is this combination a suitable option for me?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.